アルツハイマー病におけるNa+/K+比の上昇:ブラクステージの潜在的バイオマーカー
Yuma Mizuno1, Shiyue Pan2,3, Tong Zhou1
1Department of Physiology and Cell Biology, University of Nevada, Reno, NV 89557, USA.
International journal of molecular sciences
|February 13, 2026
まとめ
アルツハイマー病 アルツハイマー病 アルツハイマー病
科学分野:
- 神経科学は神経科学である.
- バイオケミストリー バイオケミストリー
- ゲロントロジーはゲロントロジーの学科です.
背景:
- アルツハイマー病 (AD) は認知機能の低下とタンパク質の蓄積を伴う.
- 研究は,ADにおけるイオン不均衡を調査するために,タンパク質集積を超えて拡大しています.
- ナトリウム (Na+) とカリウム (K+) イオンは,神経機能に不可欠です.
研究 の 目的:
- アルツハイマー病におけるNa+/K+比の変化を調査する.
- Na+/K+比がAD進行のバイオマーカーとして機能するかどうかを判断する.
主な方法:
- 97人のヒト受験者 (AD67人,対照群30人) の死後の前頭前皮質,タラマス,脳脊髄液 (CSF) の分析.
- Na+/K+比を計算するためにNa+とK+濃度の測定.
- ブラクのタングルステージとの相関分析.
主要な成果:
- Na+/K+比の有意な増加は,AD症例のタラマスとCSFで観察されました.
- 高いNa+レベルは,Na+/K+比の増加の主な要因でした.
- Na+/K+比は,ブラク・タングル・ステージと正の相関関係があり,疾患の重度を示しています.
結論:
- イオン不調,特に変化したNa+/K+比は,アルツハイマー病に関連しています.
- CSFのNa+/K+比は,ADの重症度および進行の貴重なバイオマーカーである可能性があります.
- イオン性ホメオスタシスをターゲットにすることは,ADに対する潜在的な治療の道を示しています.
関連する概念動画
01:37Neural Regulation
34.8K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
34.8K
01:26Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
01:29Alzheimer Disease l: Introduction
29
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
29
01:23Alzheimer Disease ll: Pathophysiology
42
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
42